Nextera
About[edit]
Nextera AS is a Norwegian drug discovery and target discovery company spun out from a Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. The company was founded in 2009.
Technology[edit]
NextCore Platform[edit]
Nextera's proprietary discovery platform combines deep insight into disease mechanisms with unique technology innovation. The platform integrates:
- NextCore — an integrated platform for developing precision drug candidates targeting the intracellular universe of disease antigens through pHLA (peptide-HLA)
- pIX phage display technology — core technology enabling discovery of novel antibody candidates
Pipeline[edit]
The company is developing a pipeline of TCR-Like antibody lead candidates with:
- Exquisite specificity toward disease-specific pHLA targets
- Unique potency for targeted immunotherapy
- Applications in cancer and autoimmunity
Recent Activity[edit]
- November 2025: Received funding from the Norwegian Research Council through the Innovation Project for the Industrial Sector (IPN) for development of TCR-Like antibodies in autoimmune diseases
- November 2025: Presentation at PEGS Europe 2025 in Lisbon (premier annual protein engineering conference)
- CEO/CSO Geir Aage Loset chairs sessions at PEGS Europe
Strategy[edit]
Nextera's strategy is to discover new targets and develop cognate drugs together with partners, addressing complex diseases in major indications that are currently difficult to treat.